Is peritoneal inflammation during peritoneal dialysis inhibited by drugs that block effects of substance P?

Phase 1

• Conditions: End stage renal disease under treatment with peritoneal dialysis; Therapeutic area: Analytical, Diagnostic and Therapeutic Techniques and Equipment [E] - Therapeutic techniques [E02]

• Registration Number: EUCTR2012-005063-28-SE
• Lead Sponsor: niversity of Gothenburg

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2012-11-09
• Last Update Posted: 2 June 2020

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 32

Inclusion Criteria

Included persons are treated with PD since at least 3 months and are males aged 20-90 or post-menopausal females up to age 90.
Included persons must have positive ultrafiltration (ultrafiltration volume larger than 0 ml/24 hours measured not more than one month earlier).
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 16
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 16

Exclusion Criteria

Moderate to serious liver damage, potential or known damage to the blood-brain barrier (e.g. brain tumor, meningitis, encephalitis), peritonitis during the last two months and treatment with any of the following drugs: warfarin, corticosteroider, pimozid, terfenadin, astemizol, cisaprid, ciklosporin, takrolimus, sirolimus, everolimus, alfentanil, diergotamin, ergotamin, fentanyl, kinidin, rifampicin, fenytoin, karbamazepin, fenobarbital och metotrexat.

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified